Brainsway Ltd (BWAY NASDAQ) stock market data APIs
$15.9073
0.06(0.4%)
as of October 17, 2025
Try our APIs with
free plan!
Brainsway Ltd Financial Data Overview
Price chart is built with
Anychart
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Prev. Close
15.9073
Open
15.9718
High
16.036
Low
15.3157
52 wk Range
7.84-17
Market Cap
307 M
P/E Ratio
57.1429
Shares Outstanding
19 004 K
Revenue
46 084 K
EPS
0.05
Beta
0.25
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Brainsway Ltd data using free add-ons & libraries
Get Brainsway Ltd Fundamental Data
Brainsway Ltd Fundamental data includes:
- Net Revenue: 46 084 K
- EBITDA: 3 321 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: 0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Brainsway Ltd News
New
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
BrainsWay Ltd. BWAY recently secured FDA clearance for an accelerated treatment protocol using its Deep Transcranial Magnetic Stimulation (TMS) system. The approval allows providers to treat patients ...
BrainsWay rises as FDA clears accelerated Deep TMS protocol
[FDA headquarters in Washington DC.] JHVEPhoto BrainsWay (NASDAQ:BWAY [https://seekingalpha.com/symbol/BWAY]) shares spiked on Tuesday after the U.S. FDA cleared an additional treatment protocol for ...
Brainsway stock maintains Buy rating at H.C. Wainwright after strategic investments
Investing.com - H.C. Wainwright has reiterated a Buy rating and $17.00 price target on Brainsway (NASDAQ:BWAY), the $288 million market cap medical device company that has delivered an impressive 61% ...
BWAY Shares Rise on Strategic Investment in Neurolief's At-Home Care
BrainsWay Ltd. BWAY recently took a strategic step to expand its reach in the mental health market through a $5 million investment in Neurolief Ltd., a developer of wearable, non-invasive neuromodulat...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
